NOTICE: Due to a lapse in annual appropriations, most of this website is not being updated. Learn more.
Form submissions will still be accepted but will not receive responses at this time. Sections of this site for programs using non-appropriated funds (such as NVLAP) or those that are excepted from the shutdown (such as CHIPS and NVD) will continue to be updated.
An official website of the United States government
Here’s how you know
Official websites use .gov
A .gov website belongs to an official government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you’ve safely connected to the .gov website. Share sensitive information only on official, secure websites.
Examining Resources, Initiatives, and Regulatory Pathways to Advance Regenerative Medicine Manufacturing
Published
Author(s)
Joshua Hunsberger, Martha Lundberg, Julie Allickson, Claudia Zylberberg, Sarah Beachy, Carl Simon
Abstract
This perspective article is inspired by a workshop entitled "Cell and Tissue Manufacturing Innovation" that was held at the Tissue Engineering and Regenerative medicine Society (TERMIS). Five main concepts are discussed: 1) the US National Academies' Forum on Regenerative Medicine, 2) academic translational programs, 3) developing measurements for regenerative medicine, 4) developing standards for ancillary materials and 5) the global landscape for accelerating regenerative medicine manufacturing. Concepts are presented with current perspective and key insights on challenges, opportunities and next steps for cell and tissue manufacturing innovation.
Hunsberger, J.
, Lundberg, M.
, Allickson, J.
, Zylberberg, C.
, Beachy, S.
and Simon, C.
(2019),
Examining Resources, Initiatives, and Regulatory Pathways to Advance Regenerative Medicine Manufacturing, Cytotherapy, [online], https://doi.org/10.1007/s40778-019-00163-0, https://tsapps.nist.gov/publication/get_pdf.cfm?pub_id=928015
(Accessed October 13, 2025)